What is the R&D Tax Credit?
10 November, 2010 by Tim DeanThe R&D Tax Credit legislation has had a chequered past, going through multiple revisions and stalling before entering the Senate prior to the federal election.
Government names ‘experts’ to chart course for enabling technologies
05 November, 2010 by Staff WritersThe federal government has named the 21-strong expert advisory panel who will help chart the direction of its $38.2 million National Enabling Technologies Strategy.
Government announces $160 million for four new innovation funds
05 November, 2010 by Staff WritersThe federal government today announced the formation of four new funds with a combined war chest of $160 million to support Australian innovation.
Australia and China to build new nanotechnology lab
05 November, 2010 by David BinningThe governments of Australia and China have announced that they will jointly fund a new state-of-the-art nanotechnology laboratory in China.
Applications open for 14th round of CRCs
03 November, 2010 by Staff WritersFederal innovation Minister Senator Kim Carr today announced the opening of round 14 of the CRC ( cooperative research centres) program, inviting companies around Australia to partner up and submit their applications for funding.
Aussie biotech equities under perform wider market for Q1: PWC
28 October, 2010 by Staff WritersPricewaterhouseCoopers has released its Q1FY11 BioForum report on Australia’s life sciences and biotech equities, revealing that the sector went backwards slightly as the wider market advanced.
Hatchtech raises $6.3 million for Phase IIb head lice trial
26 October, 2010 by Staff WritersMelbourne biotech Hatchtech announced today that it has raised $6.3 million to fund Phase IIb clinical trials for its novel treatment for head lice.
Market report: Healthcare index ends the week up as AusBiotech 2010 draws to a close
22 October, 2010 by David BinningThe heavy back-slapping and self-congratulations at this week’s AusBiotech 2010 shindig in Melbourne may have rubbed off a little on the S&P/ASX 200 Healthcare Index, which managed to claw back most of last week’s losses.
Australian biotech for sale
22 October, 2010 by David BinningAny doubts as to the marketability of the Australian biotech and life sciences industries were thoroughly dispelled this week with 150 investors from more than 100 companies - foreign and Australian - attending AusBiotech’s Australasian Life Sciences Investment Summit in Melbourne as part of AusBiotech 2010.
Opinion: Kim Carr on the opposition’s ‘half truths, exaggerations and blatant misrepresentations’ on R&D tax reform
19 October, 2010 by Staff WritersIt appears the Government and Opposition agree. Research and development (R&D) is fundamental to business growth and to Australia’s long term prosperity. Agreement ends at this point. We disagree on how we can get the ‘biggest bang’ out of the $1.6 billion the Government invests every year to enhance Australia’s productivity through the existing R&D tax concession.
Victorian Government announces $55m Biotechnology Action Plan
19 October, 2010 by Staff WritersVictorian Premier, John Brumby, today announced the Victorian Biotechnology Action Plan, which will provide $55 million of government money to spur biotech in the southern state.
IBM to build research lab at Melbourne University
15 October, 2010 by Staff WritersComputer giant IBM has announced that it will build a new state-of-the-art research facility at Melbourne University designed to support disease research and biotechnology as well as advance knowledge of the environment and agricultural sustainability.
Pfizer pays $3.7 billion for King Pharmaceuticals
13 October, 2010 by Staff WritersThe world’s largest pharmaceutical company Pfizer said on Tuesday that had reached an agreement to by US pain drug developer King Pharmaceuticals in a cash deal worth $3.67 billion.
Opinion: The federal government's R&D Tax Credits bill is wrong for Australia
12 October, 2010 by Staff WritersAustralians understand that innovation is an essential driver of the country’s knowledge and growth. They also recognise that research and development (R&D) activity within Australian firms assumes a crucial place in that process – through its contribution to the generation of new information, products, services and employment opportunities.
Market report: Healthcare index sneaks into positive territory for the week
10 October, 2010 by David BinningThe Australian stock market closed slightly down yesterday, bringing the week’s gains to a modest two percent, while healthcare and biotech stocks just edged into positive territory for the week.
